Given the rarity of perianal involvement, this case contributes to a broader understanding of ibrutinib-related dermatologic toxicities and highlights the need for individualized care when managing patients with CLL on BTK inhibitor therapy. Here, BTK is linked to B-cell chronic lymphocytic leukemia.